Cargando…

Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients

INTRODUCTION: Critically ill hospitalized patients are at increased risk of infection so we assessed the immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered within six days of injury. METHODS: This prospective observational study compared the immunogenicity of PPSV2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Scott W., Baumgartner, Laura J., MacLaren, Rob, Neumann, Robert, Wiktor, Arek J., Kiser, Tyree H., Lindberg, Gordon, Cava, Luis, Fish, Douglas N., Janoff, Edward N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951595/ https://www.ncbi.nlm.nih.gov/pubmed/29758059 http://dx.doi.org/10.1371/journal.pone.0197037

Ejemplares similares

Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration
por: Van Matre, Edward T., et al.
Publicado: (2017)

Complementary Role of CD4+ T Cells in Response to Pneumococcal Polysaccharide Vaccines in Humans
por: Jha, Vibha, et al.
Publicado: (2019)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
por: Kuo, Chia-Sheng, et al.
Publicado: (2016)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
por: Satomura, Kazunari, et al.
Publicado: (2014)

Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
por: Kiser, Tyree H, et al.
Publicado: (2015)

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
por: Yi, Whitley M., et al.
Publicado: (2017)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

Effect of Pneumococcal Conjugate 13 Valent and Polysaccharide 23 Valent Vaccination on Anti-Pneumococcal Antibody Titer of Hemodialysis Patients: A Randomized Clinical Trial
por: Shahi, Shima, et al.
Publicado: (2023)

Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
por: Vila-Corcoles, Angel, et al.
Publicado: (2010)

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017
por: Shimbashi, Reiko, et al.
Publicado: (2020)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
por: Wang, Yang, et al.
Publicado: (2017)

Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine
por: Whang, Yoon Hee, et al.
Publicado: (2020)

P1523: IMMUNOGENICITY OF THE 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE FOLLOWED BY THE 23-VALENT POLYSACCHARIDE VACCINE IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
por: Leach, Amanda J, et al.
Publicado: (2009)

Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan
por: Hoshi, Shu-ling, et al.
Publicado: (2015)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
por: Tomczyk, Sara, et al.
Publicado: (2014)

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
por: Matanock, Almea, et al.
Publicado: (2019)

A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV
por: Wilck, Marissa, et al.
Publicado: (2023)

Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
por: Belmonti, Simone, et al.
Publicado: (2019)

Multiple Colonization with S. pneumoniae before and after Introduction of the Seven-Valent Conjugated Pneumococcal Polysaccharide Vaccine
por: Brugger, Silvio D., et al.
Publicado: (2010)

Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae
por: Turner, Allison E.B., et al.
Publicado: (2017)

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
por: Falkenhorst, Gerhard, et al.
Publicado: (2017)

1730. Increasing Vaccination Rates of 23-valent Pneumococcal Polysaccharide Vaccine Among Patients at High-Risk for Invasive Pneumococcal Disease
por: Lyon, Edward, et al.
Publicado: (2023)

Value of the Overall Pneumococcal Polysaccharide Response in the Diagnosis of Primary Humoral Immunodeficiencies
por: Lopez, Benjamin, et al.
Publicado: (2017)

Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine
por: Thisyakorn, Usa, et al.
Publicado: (2014)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
por: MacIntyre, C. Raina, et al.
Publicado: (2014)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
por: Black, Carla L., et al.
Publicado: (2017)

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
por: Remschmidt, Cornelius, et al.
Publicado: (2016)

Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales
por: Djennad, Abdelmajid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2vlinko6l9jsg15ai9gdv75r2i